|
Es handelt sich hierbei um Investorenangst in UK. Meiner Meinung nach zum jetzigen Zeitpunkt jedoch unbegründet. What the Papers Say - Sat Feb 3 The Times Tempus headlines today that cancer cure is still the Holy Grail for the biotechnology backers. While effective treatments for the dreadful disease do exist, the wonder drug still eludes the biotech boffins. The hunt for cancer cures brought spectacular failures such as British Biotech (BBG), the former flagship of the UK`s biotech industry. Monday`s collapse into administration of Scotia Holdings (LSE: SOH.L - news) (SOH), a company with a light sensitive treatment for cancer, has done nothing to buoy confidence. In the past three years the company has spent more than £80m of shareholders money without managing to win regulatory approval for its treatment. Celltech (CCH) is unique in the UK biotechnology sector in bringing a cancer drug to market. Last year it launched an antibody-based treatment for acute leukaemia. However, Celltech is not alone in coming up with targeted treatments. Results for the phase III or late stage - trials of SR Pharma (LSE: SPA.L - news) s (SPA) non-small cell lung cancer drug are expected in the next few weeks. Antisoma (ASM) is using antibodies in a variety of different ways to fight cancer. Its lead product is at phase III trials, is designed as a compliment to surgery. Xenova (XEN) is seeking to overcome the problem of cancer cells becoming resistant to traditional chemotherapy drugs. One of its products is due to start phase III trials. The collapse of Scotia and remembrance of the British Biotech saga heightens investor fears. But the fight against cancer continues and, by providing necessary funding, investors stand to earn rewards that go farther than the mere financial. Gruß Bogo! |
|
| aus der Diskussion: | XENOVA - DISKUSSIONS-THREAD Nr. 2 (Stand: 06.11.2000) |
| Autor (Datum des Eintrages): | bogo01 (05.02.01 21:35:28) |
| Beitrag: | 33 von 275 (ID:2847456) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |